Chi-Med's fruquintinib misses OS endpoint in Phase III for third-line NSCLC

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said third-line treatment with fruquintinib missed the primary endpoint of improving overall survival (OS) vs. placebo in the Chinese Phase III FALUCA trial to treat non-small cell lung cancer.

Chi-Med did not respond to inquiries regarding next steps in time for publication, but Executive Director and CEO Christian Hogg told BioCentury in September that the company planned to submit an NDA for fruquintinib in China with a positive Phase III NSCLC readout...